drugset / Trial / NCT02870231

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

NCT02870231

Phase 1 Completed 187 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male and Female Subjects being Overweight or with Obesity

Timeline

Start
2016-08-18
Primary completion
2017-09-03
Completion
2017-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 unknown Subcutaneous
Subject Liraglutide Peptide 3 unknown Subcutaneous
Subject NNC9204-0530 Unknown Subcutaneous